Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer

Owen, JS; Rackley, RJ; Hummel, MA; Roepcke, S; Huang, HN; Liu, MR; Idris, TA; Murugesan, SMN; Marwah, A; Loganathan, S; Ranganna, G; Barve, A; Waller, CF; Socinski, MA

Owen, JS (通讯作者)，Consulting Dept, Cognigen Div Simulat Plus, Buffalo, NY 14203 USA.

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2023; 48 (6): 675

Abstract

Background and Objectives MYL-1402O is a bevacizumab (Avastin (R)) biosimilar. Pharmacokinetic and safety similarity of MYL-1402O and reference Avasti......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索